SPY302.97-0.56 -0.18%
DIA254.35-1.42 -0.56%
IXIC9,368.99-43.37 -0.46%

JMP Securities Maintains Market Outperform on Halozyme Therapeutics, Raises Price Target to $34

JMP Securities maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Outperform and raises the price target from $24 to $34.

Benzinga · 05/12/2020 15:31

JMP Securities maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Outperform and raises the price target from $24 to $34.